Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Arnott

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Inflammatory Bowel Diseases|December 20, 2007
Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysisMathew Lyons, Lauranne A A P Derikx, James Fulforth, et al.
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|October 7, 2014
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsN A Kennedy, R Kalla, B Warner, et al.
Journal of Crohn'S & Colitis|February 16, 2019
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab CohortN Plevris, C S Chuah, R M Allen, et al.
Frontline Gastroenterology|May 19, 2020
Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UKRukshana Kapasi, Jackie Glatter, Christopher A Lamb, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Large-scale single-molecule analysis of tau proteoformsJ Joly, V Budamagunta, Z Zhang, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Inflammatory Bowel Diseases|December 20, 2007
Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysisMathew Lyons, Lauranne A A P Derikx, James Fulforth, et al.
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|October 7, 2014
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsN A Kennedy, R Kalla, B Warner, et al.
Journal of Crohn'S & Colitis|February 16, 2019
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab CohortN Plevris, C S Chuah, R M Allen, et al.
Frontline Gastroenterology|May 19, 2020
Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UKRukshana Kapasi, Jackie Glatter, Christopher A Lamb, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Large-scale single-molecule analysis of tau proteoformsJ Joly, V Budamagunta, Z Zhang, et al.
Pageof 8